Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase II/III Multicenter Randomized, Double-Blind, Placebo-Controlled Platform Trial of Potential Disease Modifying Therapies Utilizing Biomarker, Cognitive, and Clinical Endpoints in Dominantly Inherited Alzheimer's Disease

NCT05269394 is registered in ClinicalTrials.gov with Washington University School of Medicine as lead sponsor.

NCT NCT05269394
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05269394 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase II/III Multicenter Randomized, Double-Blind, Placebo-Controlled Platform Trial of Potential Disease Modifying Therapies Utilizing Biomarker, Cognitive, and Clinical Endpoints in Dominantly Inherited Alzheimer's Disease
Lead sponsor
Washington University School of Medicine
Phase
Phase 2/3
Overall status
Active, not recruiting
Start date
December 22, 2021
Completion date
July 31, 2028
Enrollment
197 (actual)
Sites
36

Conditions

As the registry lists them; a condition with its own page is linked.

alzheimers disease, alzheimers disease, familial, dementia